Body Vision Medical Receives FDA Clearance for the LungVision Tool, Part of the LungVision Platform Revolutionizing the Areas of Lung Cancer Diagnostics and Treatment

The clearance paved the way for accelerating commercialization efforts. The clinical experience from multicentral study is presented at ATS 2018.

News provided by

Body Vision Medical

Apr 30, 2018, 08:00 ET

RAMAT HA SHARON, Israel, April 30, 2018 /PRNewswire/ -- Body Vision Medical, a medical device company specializing in augmented real-time imaging, artificial intelligence and intra-body navigation, announced today that it has received clearance from the U.S. Food and Drug Administration to market their LungVision Tool. The LungVision Tool is an affordable lung navigation catheter with superb maneuverability. The LungVision Tool is used in conjunction with standard bronchoscopes and the LungVision System to guide endotherapy accessories to small pulmonary nodules.

This approval clears the way for Body Vision Medical to accelerate commercialization efforts for its revolutionary LungVision Platform for pulmonary specialists across the U.S., providing an affordable and effective real-time solution for early-stage lung cancer diagnostics and treatment procedures.

The LungVison Imaging and Navigation System was cleared by the FDA in May 2017 and has been successfully used in over 290 clinical procedures in 10 leading lung cancer centers across the U.S.

"Body Vision has pioneered a new generation platform for Navigation Bronchoscopy that applies augmented reality approach to plan, visualize, and accurately track radiolucent bronchial nodules in real time," says Krish Bhadra, MD from CHI Memorial Hospital. "LungVision navigation tool has clear performance and cost benefits over current navigation tools that are bound to electro-magnetic sensing."

Body Vision CEO Dorian Averbuch added, "We are thrilled to introduce the LungVision Tool to the medical community and patients. This FDA clearance paves the way for the LungVision Platform to become the preferred choice in bronchoscopy for any Lung Cancer Center in the U.S. We envision, this affordable LungVision Platform will revolutionize the way physicians diagnose and treat peripheral lung lesions."

The clinical experience from multicentral study with the LungVision System will be presented at the American Thoracic Society Conference, held through May 18-23 in San Diego during session #C110- Interventional Pulmonology: "The swiss army knife for thoracic oncology", by Michael Pritchett, MD, Moore Regional Hospital; Krish Bhadra, MD, CHI Memorial Hospital and Pertzov Barak, MD, Rabin Medical Center on May 22, 2018 from 2:15-4:15 pm ET. Come visit Body Vision Medical booth #262

About Body Vision Medical

Body Vision Medical is a software and medical device company specializing in augmented real-time imaging, artificial intelligence and intra-body navigation. The company was founded in 2014 to address the contemporary unmet clinical need of early lung cancer diagnostics and treatment. To learn more about the company visit us at www.bodyvisionmedical.com.

Contact:
[email protected]
+1-646-8637848

SOURCE Body Vision Medical